Skip to Content

The Death of the Author and the Birth of the Contributor?

ByRichard Smith, former editor of the BMJJune 18, 2020

The following excerpt is reprinted with permission from The Trouble With Medical Journals (Taylor & Francis, 2000).

When Anthony Trollope sat down at 5.30 in the morning day after day to write his 47 novels he wrote every word. Editors and publishers no doubt proposed ideas and suggested changes. But the work was his. He was a true author. Mostly it doesn’t work like that in research. Many people with different skills are essential. Writing the paper may be one of the easiest parts of the process, and sometimes may be undertaken by a professional writer who has had nothing to do with the research. Authorship is thus, I will argue, the wrong concept for research studies, but it’s a concept with great tenacity. It is the coinage of academia, and academics have proved reluctant to move away from it to something [I] call contributorship.

Authorship is about credit and accountability. Authors are most interested in the credit, whereas editors are most concerned about accountability. Publishing papers in important journals is the main way to progress in the academic world. Those who publish the most will be promoted the fastest, win the most grants, get paid the most, and find their way to the best universities and departments. Increasingly departments and institutions are themselves judged on the amount they publish and where they publish. The cliche ‘publish or perish’ is known beyond the academic world — and is largely true. It’s often also more a matter of quantity than quality. So there are huge incentives to publish as much as possible.

The number of authors on papers has increased steadily in recent years. Some studies in molecular biology have over a hundred authors. Some of this increase is no doubt legitimate in that it reflects the increasing complexity of science and the need for teams of people with different skills. But some of this increase is probably illegitimate, driven by the need of individuals and institutions for publications: authors are included who have done little or nothing, a practice that has been called ‘gift authorship’ (164-166).

Putting your name to a paper should be like signing a cheque, a major undertaking, but often it isn’t (167). Gift authorship is a form of deception. It’s particularly troublesome to editors when there turn out to be serious problems with the paper and yet the gift authors will not accept any responsibility. I described several florid cases in chapter 8.

So who should be an author? Some academic institutions have attempted definitions, but the best known definition is that produced by the International Committee of Medical Journal Editors (which is widely known as the Vancouver group because it first met in that city in 1979) (168).

What is the legitimacy of this group to define something so important for academic life? One answer might be ‘none’. The group, of which I’ve been a member, is self-appointed and comprises the editors of the major general medical journals from the United States and Britain. There are some editors from other countries but very few, and only one or two editors are from journals not published in English. International is a misnomer. It has no constitution, no clear mission, no secretariat, no funds and no leaders. It was started by Stephen Lock, my predecessor as the editor of the BMJ, and Ed Huth, the editor of the Annals of Internal Medicine. And its great achievement was to get these major journals (and subsequently many others) to agree to use one system of referencing. This meant — in the days before word processing — that authors (or in reality their secretaries) did not have to keep retyping manuscripts as they worked their way down the food chain of journals. The group has continued to meet every one or two years and has now produced guidance on many aspects of publishing medical research. Some of this guidance has been used in institutions like the Supreme Court in the United States.

The legitimacy of the group to produce a definition of authorship (and other statements) stems partly from the fact that nobody else was doing so and partly from its potential ability to enforce the definition. Its initial definition of authorship was produced by the editors without any consultation. This meant, I judge, that it produced a definition that didn’t work in the real world. It has now, however, moved substantially towards supporting a policy of contributorship, but it continues to offer guidance on when a contributor might qualify as an author.

This is its current position (168):

‘An “author” is generally considered to be someone who has made substantive intellectual contributions to a published study, and biomedical authorship continues to have important academic, social, and financial implications. In the past, readers were rarely provided with information about contributions to studies from those listed as authors and in acknowledgments. Some journals now request and publish information about the contributions of each person named as having participated in a submitted study, at least for original research. Editors are strongly encouraged to develop and implement a contributorship policy, as well as a policy on identifying who is responsible for the integrity of the work as a whole.’

While contributorship and guarantorship policies obviously remove much of the ambiguity surrounding contributions, it leaves unresolved the question of the quantity and quality of contribution that qualify for authorship. The International Committee of Medical Journal Editors has recommended the following criteria for authorship; these criteria are still appropriate for those journals that distinguish authors from other contributors.

  • Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3.
  • Acquisition of funding, collection of data, or general supervision of the research group, alone, does not justify authorship.
  • All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
  • Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

One important change introduced by these criteria is that authors are now publicly accountable for ‘appropriate portions of the content’. It used to be that authors were expected to be publicly accountable for the whole document. Indeed, the way that I remembered the definition and explained it to others was by the story of the lead author who was about to fly to Acapulco to present the results of the study and then was suddenly taken ill. If you could get on the plane to Acapulco that day, present the paper and answer all questions you were an author. If you couldn’t, you weren’t.

Raj Bhopal, at that time a professor at Newcastle Medical School, and others conducted a study in 1996 of what academics from every part and every level of the medical school thought about the Vancouver group’s earlier definition of authorship (169). They approached 70 academics and achieved a 94% response rate. Three-quarters of those they interviewed thought that there should be criteria for authorship, but few knew of any criteria. Only 16 knew of the Vancouver group, and only five knew the three criteria, which survive in the definition quoted above. One academic of the 76 knew that you had to satisfy all the criteria in order to qualify for authorship.

Most of the academics agreed with the individual criteria of the Vancouver group, but most thought it unreasonable to expect all three to be fulfilled. The need to fulfil all three criteria was viewed as inflexible and restrictive — and prejudicial to junior researchers. Many thought that the (then) requirement to be publicly accountable for the whole study failed to recognize the real world of multidisciplinary research.

More than half of those interviewed thought that the criteria were not usually adhered to, which fits with what is now a large body of evidence that shows that only a minority of authors of studies meet all three criteria (164-166). Indeed, something like one-fifth don’t meet any of them. The Vancouver group criteria just don’t fly in the real world. Many of those interviewed in Newcastle thought it inevitable that the criteria would be breached — often for reasons of ‘power, status, and “nepotism”‘. Some didn’t recognize the authority of the Vancouver group to produce a definition of authorship.

Many of those from Newcastle — and particularly the junior researchers — thought that the Vancouver definition gave too much emphasis to intellectual input and too little to practical work. Indeed, the Vancouver definition has been called ‘a senior author’s charter’. I know about this because, although I hesitate to describe myself as a researcher, I have conducted research on aspects of medical publishing with colleagues and medical students. Often the idea is mine, and I have a rough proposal for an experimental design. But it is the others who do all the hard work, sticking stamps on envelopes, chasing those who don’t respond, and compiling and analysing the data. Without them there would be no research.

One of those interviewed in Newcastle put it this way: ‘There needs to be a difference between intellectual contribution and the execution of work. You need to have made a contribution to one or the other but it may not be realistic to have both. The criteria seem to overlook the practical, doing the experiments. They seem to say if you have ideas you become an author, if you work in the laboratory 12 hours a day you don’t get on. It should be teamwork.’

Gift authorship was seen by those in Newcastle as ‘unethical, dishonest and unacceptable’, and yet it was thought to happen commonly. The reasons given for gift authorship were (in order of importance) pressure to publish, enhancing the chances of publication (by including a ‘big name’), to repay favours, to motivate a team and encourage collaboration, and to maintain good relationships. The ‘solution’ that was most favoured was to require researchers to sign a statement justifying authorship and to specify the actual contribution of each author. Limiting the number of publications listed in a curriculum vitae or a system of fixed credits per publication found less favour.

An important aspect of the Newcastle study was to show that problems with authorship are common. Two-thirds of the academics had experienced problems, most commonly being excluded from authorship when they felt that they deserved it. Many had vivid and bitter memories of disputes over authorship. At Harvard disputes about authorship accounted for 2.3% of 355 complaints brought to the Ombuds Office in 1991-2 and 10.7% of 551 complaints in 1996-7 (170). One-third of 51 German students who had published papers reported honorary authorship of the department head, and 16 among 201 students who had done research reported that they had been omitted as author from a publication despite having contributed (171). Disputes over authorship are often the origin of the long running feuds for which the academic world is notorious. Despite most respondents in Newcastle disapproving of gift authorship, one-third of the academics had included as authors people who had done little. Gifting authorship is one of the currencies of academic life.

The overall conclusion of the Newcastle study was that: ‘The strategy for communicating and implementing the criteria of the International Committee of Medical Journal Editors has largely failed. New initiatives should engage researchers and meet their legitimate needs. Future guidelines should be developed collaboratively and not be imposed on researchers by editors.’

So the academic community and medical journals have a problem. Authorship is of fundamental importance in the academic world and yet it is corrupted. Many people appear as authors when they have done very little, but at the same time people who have done a great deal of work, usually the practical work, are excluded. How can journals respond?

One response — tried by the American journal, Obstetrics and Gynecology — was to limit the number of authors. If your paper had more than six authors you were asked to justify why. One result was that a great many papers had six authors but another was that authors submitted studies that had more than six authors elsewhere. This may have damaged the journal because major studies — like randomized controlled trials — often have more than six authors. It was a crude response to a complex problem.

Another solution suggested by the Newcastle researchers and tried by us at the BMJ was to ask everybody to sign to say that they met the Vancouver group criteria. We also tried to respond to the problem of people being excluded from authorship by asking the authors to sign to say that there wasn’t somebody who met the criteria but hadn’t been included. This solution hasn’t worked. The number of authors has not changed and later research has shown that many people who appear as authors do not meet the criteria. Editors can go only so far in ‘enforcing’ a solution, and it doesn’t feel comfortable to be operating like a policeman.

Something much more radical was suggested in JAMA in 1997 by Drummond Rennie, Veronica Yank and Linda Emmanuel (172). They suggested abandoning the concept of authorship and moving instead to contributorship. Instead of making an inevitably arbitrary decision on who was and was not an author people would simply describe their contribution. It should be possible for people to agree on who did what. It’s simply a descriptive not a judgemental exercise. The sorting of people into the sheep of authors and the goats of the merely acknowledged seems to be based, unsurprisingly, on power. The powerful even if they have done little become sheep, while hardworking goats are excluded.

The great benefit of the contributorship system in my mind is that it can be informative, precise and honest. Contributors describe exactly what they did, and readers make up their mind on the value of the contribution. By making people either authors or not lots of information is lost, and there is a pressure to be dishonest. You want to include as an author somebody who has done a great deal of work but who doesn’t feel comfortable with being publicly accountable for even part of the work. So currently they are included as an author, but readers are deceived.

One immediate problem with such a system is the need to ascertain who will take overall responsibility. Otherwise, we may be left with the problem of a dishonest paper and only ‘honest’ authors. Rennie and others suggested that all papers should have guarantors, people who accept responsibility for the full paper (172). ‘Guarantors,’ they wrote, ‘are those people who have contributed substantially, but who have also made added efforts to ensure the integrity of the entire project. They organize, oversee and double check, and must be prepared to be accountable for all parts of the completed manuscript, before and after publication.’

At the BMJ we were convinced that we needed guarantors, but we were not convinced that they had to have double checked every aspect of the research. Would this be possible if the study includes molecular biology, statistics and economics? More controversially, did the guarantor necessarily have to have contributed substantially? Mightn’t the guarantor sometimes be the person who hired all the researchers even if he or she hasn’t contributed much to the particular study? In other words, guarantorship might be akin to the responsibility of a government minister. While sat in Venice writing this book I was the guarantor of the BMJ. The buck stopped with me. I fulfilled this role not through double checking every word in the BMJ and every decision taken, but by hiring good people and creating good systems. The BMJ thus adopted the ‘ministerial’ version of the guarantor, and, interestingly, it potentially revived in some way the tradition of heads of department putting their names on papers just as people countersign cheques.

The idea of Rennie and others was radical — and so naturally there were objections. People have described the contributorship system as being like ‘film credits’, and one anxiety was that studies would accumulate enormous lists of contributors — down to the ‘principal lady’s baggage carrier’. This has not happened. In fact the opposite has happened in that the sum of the contributions turns out to be less than the work that clearly had to be done. For example, papers have been published that nobody has written. Those journals — like the Lancet and the BMJ — that have adopted the system have so far allowed contributors to produce their own statement in straight text. The BMJ did plan to experiment with a matrix system, where the journal would list the activities that we knew had to be undertaken to complete and publish a study (conception, design, data collection and analysis, writing and correcting the paper) and then ask for an indication of which author did what. We didn’t want to be restrictive and would have allowed authors to add tasks that were not in our routine list.

Another objection is that the contributorship devalues authorship. All sorts of ragamuffins are now included. But the beauty of the system in my mind is that there should be no pretence, no deceit. If the ragamuffins simply made the tea then the contributorship statement will say so. Disclosure is once again a panacea.

One problem that is potentially solved by the system of contributorship is the problem of the ‘ghost author’, somebody who simply writes the paper. Such people are often employed by pharmaceutical companies, which has prompted great anxiety. Clearly nobody can be happy with a distinguished doctor receiving a ready written review article that is to be submitted to a major journal and being asked to append his name in exchange for $10,000. A bold doctor might be willing to declare that his contribution was to sign his name and bank the cheque, but this is a degree of deception that cannot be tolerated. Unfortunately, it happens, although I know of no data that say how often.

I did, however, recently meet a professor who told me that he sat next to a woman on a plane — in business class — who boasted that she had published more papers in major medical journals, including the BMJ, than any other living author. Yet her name, she said, never appeared. She was a champion ghostwriter and employed by pharmaceutical companies.

What is known to happen commonly is that a professional writer writes the paper. The other contributors will read the paper and make changes, but the professional writer does the donkey work of getting the first draft written. To my mind, this is no different from using a statistician, somebody with special skills, and is perfectly acceptable so long as it’s declared. Others differ. They think that the process of writing creates ideas and allows bias to suffuse through the paper. Professional writers should thus be banned. If a scientific paper were a novel or a poem I would agree, but it’s not. It should be as clear a statement as possible of what was done and found. Those parts of a scientific paper that are closest to a novel — the introduction and discussion — should be cut back ruthlessly. Furthermore, the other contributors — and particularly the guarantor — must approve every word of the final study. They are, I keep repeating, signing a cheque.

A more important objection to the system of contributorship is that the academic system of credit depends on authorship, and some journals moving away from authorship messes up the academic system. People who have contributed small amounts to a study will be seen as authors by a system that simply counts the names attached to a study. I can see the problem, but for me it is an argument not for editors abandoning contributorship but for academics adopting a more sophisticated system.

The information included in contributorship statements should be very useful to those awarding credits or making appointments. Do you want to appoint an ‘ideas’ person or somebody who is better at implementation? Contributorship statements will give you this information in a way that lists of authors will not.

Despite my enthusiasm for the concept of contributorship it has not been widely adopted. This is, I think, mainly a matter of time and conservatism — and there has been steady movement in the direction of contributorship by the International Committee of Medical Journal Editors. It can’t, however, take the logical step of abandoning authorship and moving wholesale to contributorship. Nor, I have to say, did the BMJ while I was editor. Academic medicine is stultifyingly conservative. It’s something to do with fear. Those academics who have fought their way to the top of the pile have done so through the present system. Any change in the system might expose the fragility they feel in their hearts.

A subject that I must discuss despite its unimportance is the order of contributors — because, although unimportant, it causes great distress. When correcting the first draft of this chapter I was in correspondence with a contributor ready to take extreme steps in a dispute over order of contributorship. I argued that she was fighting a battle without meaning, but she didn’t agree. I argued that the battle was meaningless because order of contributorship is uninterpretable. The traditions over order vary among disciplines, specialties, institutions and departments. Sometimes the ‘senior’ contributor (in itself a phrase with little meaning) is first, sometimes last, sometimes in the middle. Unless readers have the traditions explained to them they can’t infer anything from the order.

The Vancouver group has this to say (168):

‘The order of authorship on the byline should be a joint decision of the co-authors. Authors should be prepared to explain the order in which authors are listed.’

The adoption of contributorship statements would make the debate over the order of contributorship irrelevant. The information a reader might need is in the statement. But Rennie and others suggest that contributors meet together and agree on the relative sizes of their contributions and then list themselves in order of size of contribution. This is of course a matter of comparing apples and oranges (how does having the idea while in the bath compare with six weeks of data collection in the street?), and with such processes the powerful are likely to come out on top.

I want to end this chapter by commenting on an interesting paper by Richard Horton, the editor of the Lancet, that suggests that the idea that all the contributors to a study agree with its conclusions is often false. He builds on the insight of the French philosopher Simone Weill that, ‘All sentences that begin with “we” are lies.’ We can never know exactly what each other thinks. I use the quote whenever I talk about the media, a plural noun. The same might be said of sentences that begin ‘Doctors…’ or ‘Medical journals…’ There are probably many such sentences in this book. They are inescapable.

Horton began with the observation that there have been some high profile studies — for example, an Italian trial on the treatment of acute stroke — where contributors have disagreed openly, and sometimes bitterly, about the meaning of their study. (173-175). He selected 10 papers published in the Lancet in 2000 and wrote to the 54 contributors asking about the studies’ results, strengths and weaknesses, interpretation, implications, and meaning for further research. Overall he found substantial disagreement among contributors, but this diversity of views was not reflected in the published papers. Weaknesses of the study were played down, and the discussion section of papers was poorly organized and didn’t address many scientific questions that they should have addressed.

Perhaps we shouldn’t be surprised by this. Simone Weill has pointed out the problem, and we know that many people describing a comparatively simple event will give very different descriptions. As the film maker Robert Evans said, ‘There are three sides to every story: yours, mine, and the truth.’ This might be extended upwards to any number of people, and the only version that I would disbelieve completely would be that labelled ‘the truth’. Who would produce it?

One response to the problem Horton has identified might be to require structured discussions, a suggestion that I made together with Mike Doherty, who was at the time the editor of the Annals of Rheumatic Diseases (176). But a more interesting response might be to make discussions exactly what the word implies. Instead of presenting one discussion contributors might display their different views.

Moves away from authorship towards contributorship, and possible future moves to reflect the diversity of views of contributors, all help to move us beyond the illusion of a scientific paper as an objective artefact to a living, human and therefore imperfect document.

More From The Trouble With Medical Journals


  1. Wakefield AJ, Murch SH, Linnell AAJ et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis and pervasive developmental disorder in children. Lancet 1998;351:637-41.
  2. Laumann E, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44 (published erratum appears in JAMA 1999;281:1174).
  3. Moynihan R. The making of a disease: female sexual dysfunction. BMJ 2003;326:45-7.
  4. Hudson A, McLellan F. Ethical issues in biomedical publication. Baltimore: Johns Hopkins University Press, 2000.
  5. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. London: Little, Brown, 1991.
  6. Haynes RB. Where’s the meat in clinical journals? ACP Journal Club 1993;119:A23-4.
  7. Altman DG. The scandal of poor medical research. BMJ 1994;308:283-4.
  8. Shaughnessy AF, Slawson DC, Bennett JH. Becoming an information master: a guidebook to the medical information jungle. J Fam Pract 1994;39:489-99.
  9. Bartrip P. Mirror of medicine: a history of the BMJ. Oxford: British Medical Journal and Oxford University Press, 1990.
  10. Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental? Lancet 1998;351:611-12.
  11. Pobel D, Viel JF. Case-control study of leukaemia among young people near La Hague nuclear reprocessing plant: the environmental hypothesis revisited. BMJ 1997;314:101.
  12. Horton R. A statement by the editors of the Lancet. Lancet 2004;363:820-1.
  13. Murch SH, Anthony A, Casson DH et al. Retraction of an interpretation. Lancet 2004;363:750.
  14. Smith R. The discomfort of patient power. BMJ 2002;324:497-8.
  15. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.
  16. Cleland JGF. For debate: Preventing atherosclerotic events with aspirin. BMJ 2002;324:103-5.
  17. Bagenal FS, Easton DF, Harris E et al. Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet 1990;336:606-10.
  18. Fox R. Quoted in: Smith R. Charity Commission censures British cancer charities. BMJ 1994;308:155-6.
  19. Richards T. Death from complementary medicine. BMJ 1990;301:510.
  20. Goodare H. The scandal of poor medical research: sloppy use of literature often to blame. BMJ 1994;308:593.
  21. Bodmer W. Bristol Cancer Help Centre. Lancet 1990;336:1188.
  22. Budd JM, Sievert ME, Schultz TR. Phenomena of retraction. Reasons for retraction and citations to the publications. JAMA 1998;280:296-7.
  23. McVie G. Quoted in: Smith R. Charity Commission censures British cancer charities. BMJ 1994;308:155-6.
  24. Smith R. Charity Commission censures British cancer charities. BMJ 1994;308:155-6.
  25. Feachem RGA, Sekhri NK, White KL. Getting more for their dollar: a comparison of the NHS with California’s Kaiser Permanente. BMJ 2002;324:135-41.
  26. Himmelstein DU, Woolhandler S, David DS et al. Getting more for their dollar: Kaiser v the NHS. BMJ 2002;324:1332.
  27. Talbot-Smith A, Gnani S, Pollock A, Pereira Gray D. Questioning the claims from Kaiser. Br J Gen Pract 2004;54:415-21.
  28. Ham C, York N, Sutch S, Shaw R. Hospital bed utilisation in the NHS, Kaiser Permanente, and the US Medicare programme: analysis of routine data. BMJ 2003;327:1257-61.
  29. Sanders SA, Reinisch JM. Would you say you ‘had sex’ If…? JAMA 1999;281:275-7.
  30. Anonymous. lfs over, Debbie. JAMA 1988;259:272.
  31. Lundberg G. ‘lfs over, Debbie,’ and the euthanasia debate. JAMA 1988;259:2142-3.
  32. Smith R. Euthanasia: time for a royal commission. BMJ 1992;305:728-9.
  33. Doyal L, Doyal L. Why active euthanasia and physician assisted suicide should be legalised. BMJ 2001;323:1079-80.
  34. Emanuel EJ. Euthanasia: where The Netherlands leads will the world follow? BMJ 2001;322:1376-7.
  35. Angell M. The Supreme Court and physician-assisted suicide-the ultimate right N Eng J Med 1997;336:50-3.
  36. Marshall VM. lfs almost over — more letters on Debbie. JAMA 1988;260:787.
  37. Smith R. Cheating at medical school. BMJ 2000;321:398.
  38. Davies S. Cheating at medical school. Summary of rapid responses. BMJ 2001;322:299.
  39. Ewen SWB, Pusztai A. Effects of diets containing genetically modified potatoes expressing Galanthus nivalis lactin on rat small intestine. Lancet 1999;354:1353-4.
  40. Horton R. Genetically modified foods: ‘absurd’ concern or welcome dialogue? Lancet 1999;354:1314-15.
  41. Kuiper HA, Noteborn HPJM, Peijnenburg AACM. Adequacy of methods for testing the safety of genetically modified foods. Lancet 1999;354:1315.
  42. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 2000;343:1520-8.
  43. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., ‘Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis.’ N Eng J Med 2000;343:1520-8. N Eng J Med 2005;353:2813-4.
  44. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Eng J Med 2006;354: 1193.
  45. Laumann E, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44 (published erratum appears in JAMA 1999;281:1174).
  46. Smith R. In search of ‘non-disease.’ BMJ 2002;324:883-5.
  47. Hughes C. BMJ admits ‘lapses’ after article wiped £30m off Scotia shares. Independent 10 June 2000.
  48. Hettiaratchy S, Clarke J, Taubel J, Besa C. Burns after photodynamic therapy. BMJ 2000;320:1245.
  49. Bryce R. Burns after photodynamic therapy. Drug point gives misleading impression of incidence of burns with temoporfin (Foscan). BMJ 2000;320:1731.
  50. Richmond C. David Horrobin. BMJ 2003;326:885.
  51. Enstrom JE, Kabat GC. Environmental tobacco smoke and tobacco related mortality in a prospective study of Californians, 1960-98. BMJ 2003;326:1057-60.
  52. Roberts J, Smith R. Publishing research supported by the tobacco industry. BMJ 1996;312:133-4.
  53. Lefanu WR. British periodicals of medicine 1640-1899. London: Wellcome Unit for the History of Medicine, 1984.
  54. Squire Sprigge S. The life and times of Thomas Wakley. London: Longmans, 1897.
  55. Bartrip PWJ. Themselves writ large: the BMA 183~1966. London: BMJ Books, 1996.
  56. Delamothe T. How political should a general medical journal be? BMJ 2002;325:1431-2.
  57. Gedalia A. Political motivation of a medical joumal [electronic response to Halileh and Hartling. Israeli-Palestinian conflict]. BMJ 2002. (accessed 10 Dec 2002).
  58. Marchetti P. How political should a general medical journal be? Medical journal is no place for politics. BMJ 2003;326:1431-32.
  59. Roberts I. The second gasoline war and how we can prevent the third. BMJ 2003;326:171.
  60. Roberts IG. How political should a general medical journal be? Medical journals may have had role in justifying war. BMJ 2003;326:820.
  61. Institute of Medicine. Crossing the quality chasm. Anew health system for the 21st century. Washington: National Academy Press, 2001.
  62. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Can Med Assoc J 1995;153:1423-31.
  63. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317-22.
  64. Grol R. Beliefs and evidence in changing clinical practice. BMJ 1997;315:418-21.
  65. Smith R. What clinical information do doctors need? BMJ 1996;313:1062-8.
  66. Godlee F, Smith A, Goldman D. Clinical evidence. BMJ 1999;318:1570-1.
  67. Smith R. The BMJ: moving on. BMJ 2002;324:5-6.
  68. Milton J. Aeropagitica. World Wide Web: Amazon Press (digital download), 2003.
  69. Coulter A. The autonomous patient ending paternalism in medical care. London: Stationery Office Books, 2002.
  70. Muir Gray JA. The resourceful patient. Oxford: Rosetta Press, 2001.
  71. World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health. Geneva: WHO, 2001.
  72. Mullner M, Groves T. Making research papers in the BMJ more accessible. BMJ 2002;325:456.
  73. Godlee F, Jefferson T, eds. Peer review in health sciences, 2nd edn. London: BMJ Books, 2003.
  74. Reiman AS. Dealing with conflicts of interest. N Eng J Med 1984;310:1182-3.
  75. Hall D. Child protection: lessons from Victoria Climbié. BMJ 2003;326:293-4.
  76. McCombs ME, Shaw DL. The agenda setting function of mass media. Public Opin Q 1972;36:176-87.
  77. McCombs ME, Shaw DL. The evolution of agenda-setting research: twenty five years in the marketplace of ideas. J Commun 1993;43:58-67.
  78. Edelstein L. The Hippocratic oath: text, translation, and interpretation. Baltimore: Johns Hopkins Press, 1943.
  79. (accessed 8 June 2003).
  80. Weatherall DJ. The inhumanity of medicine. BMJ 1994;309:1671-2.
  81. Smith R. Publishing information about patients. BMJ 1995;311:1240-1.
  82. Smith R. Informed consent: edging forwards (and backwards). BMJ 1998;316:949-51 .
  83. Calman K. The profession of medicine. BMJ 1994;309:1140-3.
  84. Smith R. Medicine’s core values. BMJ 1994;309:1247-8.
  85. Smith R. Misconduct in research: editors respond. BMJ 1997;315:201-2.
  86. McCall Smith A, Tonks A, Smith R. An ethics committee for the BMJBMJ 2000;321:720.
  87. Smith R. Medical editor lambasts journals and editors. BMJ 2001;323:651.
  88. Smith R, Rennie D. And now, evidence based editing. BMJ 1995;311:826.
  89. Weeks WB, Wallace AE. Readability of British and American medical prose at the start of the 21st century. BMJ 2002;325:1451-2.
  90. O’Donnell M. Evidence-based illiteracy: time to rescue ‘the literature’. Lancet 2000;355:489-91 .
  91. O’Donnell M. The toxic effect of language on medicine. J R Coli Physicians Lond 1995;29:525-9.
  92. Berwick D, Davidoff F, Hiatt H, Smith R. Refining and implementing the Tavistock principles for everybody in health care. BMJ 2001;323:616-20.
  93. Gaylin W. Faulty diagnosis. Why Clinton’s health-care plan won’t cure what ails us. Harpers 1993;October:57-64.
  94. Davidoff F. Reinecke RD. The 28th Amendment. Ann Intern Med 1999;130:692-4.
  95. Davies S. Obituary for David Horrobin: summary of rapid responses. BMJ 2003;326: 1089.
  96. Butler D. Medical journal under attack as dissenters seize AIDS platform. Nature 2003;426:215.
  97. Smith R. Milton and Galileo would back BMJ on free speech. Nature 2004;427:287.
  98. Carr EH. What is histoty? Harmondsworth: Penguin, 1990.
  99. Popper K. The logic of scientific discovery. London: Routledge, 2002.
  100. Kuhn T. The structure of scientific revolutions. London: Routledge, 1996.
  101.,11718,850815,00.html (accessed 14 June 2003).
  102. Davies S, Delamothe T. Revitalising rapid responses. BMJ 2005;330:1284.
  103. Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. BMJ 2003;326:1 083-4.
  104. Horton R. Surgical research or comic opera: questions, but few answers. Lancet 1996;347:984-5.
  105. Pitches D, Burls A, Fry-Smith A. How to make a silk purse from a sow’s ear — a comprehensive review of strategies to optimise data for corrupt managers and incompetent clinicians. BMJ 2003;327:1436-9.
  106. Poloniecki J. Half of all doctors are below average. BMJ 1998;316:1734-6.
  107. Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
  108. Shumaker SA, Legault C, Thai L et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
  109. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984;3:409-22.
  110. Leibovici L. Effects of remote, retroactive intercessory prayer on outcomes in patients with bloodstream infection: randomised controlled trial. BMJ 2001;323:1450-1.
  111. Haynes RB, McKibbon A, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996;348:383-6.
  112. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
  113. Altman DG, Schulz KF, Moher D et al., for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
  114. Moher D, Jones A, Lepage L; CONSORT Group (Consolitdated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285:1992-5.
  115. Garattini S, Bertele V, Li Bassi L. How can research ethics committees protect patients better? BMJ 2003;326:1199-201.
  116. Sackett Dl, Oxman AD. HARLOT pic: an amalgamation of the world’s two oldest professions. BMJ 2003;327:1442-5.
  117. loannidis JPA. Why most published research findings are false. PLoS Med 2005;2:e124.
  118. Greenhalgh T. How to read a paper. London: BMJ Books, 1997.
  119. Sterne JAC, Davey Smith G. Sifting the evidence: what’s wrong with significance tests? BMJ 2001;322:226-31.
  120. Le Fanu J. The rise and fall of modem medicine. New York: Little, Brown, 1999.
  121. Lock S. A difficult balance: editorial peer review in medicine. London: Nuffield Provincials Hospital Trust, 1985.
  122. Rennie D. Guarding the guardians: a conference on editorial peer review. JAMA 1986;256:2391-2.
  123. Martyn C. Slow tracking for BMJ papers. BMJ 2005;331:1551-2.
  124. Hwang WS, Roh Sl, Lee BC et al. Patient-specific embryonic stem cells derived from human SCNT blastocysts. Science 2005;308:1777-83.
  125. Normile D, Vogel G, Holden C. Stem cells: cloning researcher says work is flawed but claims results stand. Science 2005;310:1886-7.
  126. Jefferson T, Alderson P, Wager E, Davidoff F. Effects of editorial peer review: a systematic review. JAMA 2002;287:2784-6.
  127. Godlee F, Gale CR, Martyn CN. Effect on the quality of peer review of blinding reviewers and asking them to sign their reports: a randomized controlled trial. JAMA 1998;280:237-40.
  128. Schroter S, Black N, Evans S et al. Effects of training on quality of peer review: randomised controlled trial. BMJ 2004;328:673.
  129. Peters D, Ceci S. Peer-review practices of psychological journals: the fate of submitted articles, submitted again. Behav Brain Sci 1982;5:187-255.
  130. McIntyre N, Popper K. The critical attitude in medicine: the need for a new ethics. BMJ 1983;287:1919-23.
  131. Horton R. Pardonable revisions and protocol reviews. Lancet 1997;349:6.
  132. Rennie D. Misconduct and journal peer review. In: Godlee F, Jefferson T, eds. Peer review in health sciences. London: BMJ Books, 1999.
  133. McNutt RA, Evans AT, Fletcher AH, Fletcher SW. The effects of blinding on the quality of peer review. A randomized trial. JAMA 1990;263:1371-6.
  134. Justice AC, Cho MK, Winker MA, Berlin JA, Rennie D, the PEER investigators. Does masking author identity improve peer review quality: a randomized controlled trial. JAMA 1998;280:240-2.
  135. van Rooyen S, Godlee F, Evans S et al. Effect of blinding and unmasking on the quality of peer review: a randomized trial. JAMA 1998;280:234-7.
  136. Fabiato A. Anonymity of reviewers. Cardiovasc Res 1994;28:1134-9.
  137. Fletcher RH, Fletcher SW, Fox R et al. Anonymity of reviewers. Cardiovasc Res 1994;28:1340-5.
  138. van Rooyen S, Godlee F, Evans S et al. Effect of open peer review on quality of reviews and on reviewers’ recommendations: a randomised trial. BMJ 1999;18:23-7.
  139. Lock S. Research misconduct 1974-1990: an imperfect history. In: Lock S, Wells F, Farthing M, eds. Fraud and misconduct in biomedical research, 3rd edn. London: BMJ Books, 2001.
  140. Rennie D, Gunsalus CK. Regulations on scientific misconduct: lessons from the US experience. In: Lock S, Wells F, Farthing M, eds. Fraud and misconduct in biomedical research, 3rd edn. London: BMJ Books, 2001.
  141. Royal College of Obstetricians and Gynaecologists. Report of the independent committee of inquiry into the circumstances surrounding the publication of two articles in the British Journal of Obstetrics and Gynaecology in August 1994. London: RCOG, 1995.
  142. Lock S. Lessons from the Pearce affair: handling scientific fraud. BMJ 1995;310:1547.
  143. Pearce JM, Manyonda IT, Chamberlain GVP. Tenn delivery after intrauterine relocation of an ectopicpregnancy. Br J Obstet Gynaecol 1994;101:716-17.
  144. Pearce JM, Hamid RI. Randomised controlled trial of the use of human chorionic gonadotrophin in recurrent miscarriage associated with polycystic ovaries. Br J Obstet Gynaecol 1994;101:685-8.
  145. Wilmshurst P. Institutional corruption in medicine. BMJ 2002;325:1232-5.
  146. Smith R. What is research misconduct? In: Nimmo WS, ed. Joint Consensus Conference on Research Misconduct in Biomedical Research. J R Coli Phys Edin 2000;30 (Suppl 7): 4-8.
  147. Integrity and misconduct in research. Report of the Commission on Research Integrity to the Secretary of Health and Human Services, the House Committee on Commerce, and the Senate Committee on Labor and Human resources. 3 November 1995. (accessed 10 July 2003).
  148. Office of Science and Technology Policy, Executive office of the President. Federal policy on research misconduct. Federal Register 6 December 2000, pp 76260-4. (accessed 10 July 2003).
  149. Nylenna M, Andersen D, Dahlquist G et al. on behalf of the National Committees on Scientific Dishonesty in the Nordic Countries. Handling of scientific dishonesty in the Nordic countries. Lancet 1999;354:57-61.
  150. Joint Consensus Conference on Misconduct in Biomedical Research. Consensus statement. 28 and 29 October 1999. (accessed 10 July 2003).
  151. Zuckerman H. Scientific elite: Nobel laureates in the United States. New York: Free Press, 1977.
  152. Rennie SC, Crosby JR. Are ‘tomorrow’s doctors’ honest? Questionnaire study exploring medical students’ attitudes and reported behaviour on academic misconduct. BMJ 2001;322:274-5.
  153. Lock S. Misconduct In medical research: does it exist In Britain? BMJ 1988;297:1531-5.
  154. Smith R. Draft code of conduct for medical editors. BMJ 2003;327:1010.
  155. Stoa-Birketvedt G. Effect of cimetidine suspension on appetite and weight in overweight subjects. BMJ 1993;306:1091-3.
  156. Rasmussen MH, Andersen T, Breum L et al. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. BMJ 1993;306:1093-6.
  157. Garrow J. Does cimetidine cause weight loss? BMJ 1993;306:1084.
  158. White C. Suspected research fraud: difficulties of getting at the truth. BMJ 2005;331:281-8.
  159. Smith R. Investigating the other studies of a possibly fraudulent author. BMJ 2005;331 :288-91.
  160. Chandra RK. Effect of vitamin and trace-element supplementation on cognitive function in elderly subjects. Nutrition 2001;17:709-12.
  161. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet 1992;340:1124-7.
  162. Meguid M. Retraction of: Chandra RK. Nutrition 2001;17:709-12. Nutrition 2005;21:286.
  163. Carpenter RK, Roberts S, Sternberg S. Nutrition and immune function: a 1992 report. Lancet 2003;361:2247.
  164. Shapiro OW, Wenger WS, Shapiro MF. The contributions of authors to multiauthored biomedical research papers. JAMA 1994;271:438-42.
  165. Goodman N. Survey of fulfilment of criteria of authorship in published medical research. BMJ 1994;309:1482.
  166. Flanagin A, Carey LA, Fontanarosa PB et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998;280:222-4.
  167. Horton R. The signature of responsibility. Lancet 1997;350:5-6.
  168. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. (accessed 15 April 2006).
  169. Bhopal R, Rankin J, McColl E et al. The vexed question of authorship: views of researchers in a British medical faculty. BMJ 1997;314:1009.
  170. Wilcox LJ. Authorship. The coin of the realm. The source of complaints. JAMA 1998;280:216-17.
  171. Eysenbach G. Medical students and scientific misconduct: survey among 229 students., 3 February 2001.
  172. Rennie D, Yank V, Emanuel L. When authorship fails: a proposal to make contributors accountable. JAMA 1997;278:579-85.
  173. Horton R. The hidden research paper. JAMA 2002;287:2775-8.
  174. MAST-I Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
  175. Tognoni G, Roncaglioni MC. Dissent: an alternative interpretation of MAST-I. Lancet 1995;346:1515.
  176. Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ 1999;318:1224-5.

Comments on The Death of the Author and the Birth of the Contributor?


Comment thread URL copied!